Creutzfeldt-Jakob Disease (CJD) is a rare, fatal, and rapidly progressive neurodegenerative disorder classified as a transmissible spongiform encephalopathy (TSE) or prion disease. CJD results from the misfolding of the normal cellular prion protein (PrP^C) into the pathogenic scrapie prion protein (PrP^Sc). This page covers the current therapeutic approaches for CJD, including symptomatic management, experimental therapies, and supportive care strategies[@prusiner1998].
Pathophysiology Overview
CJD is caused by the accumulation of abnormal prion proteins (PrP^Sc) in the brain, leading to spongiform degeneration, neuronal loss, and rapid cognitive and motor decline. The disease can occur in sporadic, genetic, iatrogenic, or variant forms. The median survival time after symptom onset is 4-6 months, with most patients succumbing within 1-2 years[@prusiner1998].
Current Therapeutic Approaches
Symptomatic Management
Currently, there are no disease-modifying therapies approved for CJD. Treatment focuses on symptomatic relief and improving quality of life[@collins2004]:
Pharmacological Symptom Control
Non-Pharmacological Approaches
Multidisciplinary care team: Neurology, palliative care, speech therapy, physical therapy, occupational therapy
Nutritional support: Early assessment for dysphagia, consideration of PEG tube placement in advanced cases
Physical therapy: Range of motion exercises, positioning to prevent contractures
Speech therapy: For dysarthria and dysphagia management
Disease-Modifying Experimental Therapies
Several therapeutic approaches are under investigation for CJD[@caughey2003][@geschwind2015]:
Antemortem Therapy Candidates
Targeting Prion Protein Misfolding
Prion protein aggregation inhibitors: Small molecules that prevent the conversion of PrP^C to PrP^Sc
[Collins SJ, Lawson VA, Masters CL, Transmissible spongiform encephalopathies (2004)](https://doi.org/10.1016/S1474-4422(04)
[Caughey B, Lansbury PT, Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders (2003)](https://doi.org/10.1146/annurev.neuro.26.010302.081142)